Review of the development of cyanate as a drug in the treatment of sickle cell anemia.
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy*; D000818:Animals; D001663:Bilirubin / Q000097:blood; D001665:Binding Sites; D002245:Carbon Dioxide / Q000097:blood; D002250:Carbon Radioisotopes; D002470:Cell Survival / Q000187:drug effects; D002857:Chromium; D003485:Cyanates / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D004912:Erythrocytes / Q000187:drug effects / Q000502:physiology; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D051379:Mice; D009928:Organ Specificity; D010100:Oxygen / Q000097:blood; D011485:Protein Binding; D013997:Time Factors; D014633:Valine
D002250:Carbon Radioisotopes; D003485:Cyanates; D006454:Hemoglobins; D002857:Chromium; D002245:Carbon Dioxide; D007770:L-Lactate Dehydrogenase; D014633:Valine; D001663:Bilirubin; D010100:Oxygen